Abbott plains to appeal the patent infringement after a jury ruled that Abbott"s best-selling drug, Humira [adalimumab], violated a patent on Johnson & Johnson"s Remicade [infliximab]. Both drugs are approved to treat a variety of immune disorders. In May, Abbott filed suit claiming that J & J infringed on Humira"s patents in the development of J&J"s Simponi launced as successor to Remicade.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지